CDH2 and prostate carcinoma: An evaluation of gene expression revealed that in all three prostate cancer cell lines, treatment with MCM was more effective than FCM in reducing the expression of N‐Cadherin and Vimentin, EGFR and BCL2 genes (p < 0.001).